Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K, Itoh O, Nishimura T
Central Research Laboratory, Nihon Medi-Physics Co., Ltd., Chiba, Japan.
J Nucl Med. 1995 Jun;36(6):1043-50.
Increased clinical use of 123I-labeled 15-(p-iodophenyl)-3-(R,S)-methyl- pentadecanoic acid ([123I]BMIPP) revealed discordance between BMIPP uptake and that of perfusion agents, which was inexplicable due to the uncertainty of its myocardial metabolism. This study clarifies the metabolic fate of BMIPP and its relation to substrates in isolated rat hearts.
Rat hearts were perfused with 5 mmole/liter HEPES buffer containing various energy substrates and 1% bovine serum albumin. The buffer was recirculated for 4 hr after bolus injection of [123I]BMIPP. Heart time-activity curves were monitored externally. After perfusion, the radioactivity in the heart and recirculated buffer was measured. The metabolites in the buffer were then extracted and analyzed by HPLC and TLC.
when 0.4 mmole/liter oleate was the energy substrate, more than eight radioactive BMIPP metabolites were detected. The metabolites in the coronary effluent depended on the energy substrate in the buffer. The radioactivity in the heart at the end of the perfusion period was significantly higher when 0.4 mmole/liter oleate (28.0% +/- 1.2% ID/g, mean +/- s.e.m.) or 10 mmole/liter glucose with 25 U/liter insulin (43.9% +/- 2.2% ID/g) were the substrates compared to when 5 mmole/liter acetate (8.5% +/- 0.4% ID/g) or 0.4 mmole/liter cold BMIPP (6.2% +/- 0.3% ID/g) were the substrates. The distribution of metabolites suggests that oleate stimulated both alpha and beta oxidations, whereas glucose with insulin inhibited both. Acetate also stimulated alpha oxidation but not beta oxidation. Cold BMIPP strongly inhibited both alpha- and beta-oxidations, and little alpha oxidation occurred compared to beta-oxidation.
These results suggest that [123I]BMIPP is metabolized in the myocardium and the metabolism is closely related to myocardial carbohydrate utilization.
123I标记的15-(对碘苯基)-3-(R,S)-甲基十五烷酸([123I]BMIPP)在临床上的使用增加,结果显示BMIPP摄取与灌注剂摄取之间存在不一致,由于其心肌代谢的不确定性,这种不一致无法解释。本研究阐明了BMIPP在离体大鼠心脏中的代谢命运及其与底物的关系。
用含各种能量底物和1%牛血清白蛋白的5毫摩尔/升HEPES缓冲液灌注大鼠心脏。在推注[123I]BMIPP后,缓冲液循环4小时。外部监测心脏时间-活性曲线。灌注后,测量心脏和循环缓冲液中的放射性。然后提取缓冲液中的代谢物,并通过HPLC和TLC进行分析。
当0.4毫摩尔/升油酸作为能量底物时,检测到八种以上放射性BMIPP代谢物。冠状动脉流出液中的代谢物取决于缓冲液中的能量底物。与以5毫摩尔/升乙酸盐(8.5%±0.4%ID/g)或0.4毫摩尔/升冷BMIPP(6.2%±0.3%ID/g)作为底物相比,当以0.4毫摩尔/升油酸(28.0%±1.2%ID/g,平均值±标准误)或10毫摩尔/升葡萄糖加25单位/升胰岛素(43.9%±2.2%ID/g)作为底物时,灌注期末心脏中的放射性显著更高。代谢物的分布表明,油酸刺激α和β氧化,而葡萄糖加胰岛素则抑制两者。乙酸盐也刺激α氧化,但不刺激β氧化。冷BMIPP强烈抑制α和β氧化,与β氧化相比,α氧化很少发生。
这些结果表明,[123I]BMIPP在心肌中代谢,且该代谢与心肌碳水化合物利用密切相关。